Rule 3.19A.3

Appendix 3Z

Final Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001.

Name of entity: AVITA Medical, Inc. ("Company")

ARBN: 641 288 155

We (the entity) give ASX the following information under listing rule 3.19A.3 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of director	Michael Perry
Date of last notice	29 November 2022
Date that director ceased to be director	12 December 2022 (United States) / 13 December 2022 (Australia)

Part 1 – Director's relevant interests in securities of which the director is the registered holder *In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust*

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Number & class of securities

634,602 CHESS Depositary Interests in the Company quoted on the ASX ("CDIs") (representing beneficial ownership in 126,920 shares of common stock in the Company ("Shares"))

102,579 Shares

NB: As disclosed in Dr Perry's last notice of 29 November 2022, Dr Perry also held 23,800 unquoted restricted stock units in the Company to acquire Shares (which may be represented by CDIs) (the "RSUs"). The RSUs were forfeited on the date that Dr Perry ceased to be a director of the Company, being 12 December 2022 (United States) / 13 December 2022 (Australia), in accordance with the terms of the RSUs.

NB: As disclosed in Dr Perry's last notice of 29 November 2022, Dr Perry also held 20,700 unquoted options in the Company to acquire Shares (which may be represented by CDIs) (the "Options"). Of the Options, 13,800 Options were unvested (the "Unvested Options") while the remainder (6,900 Options) were vested (the "Vested Options"). The Unvested Options were cancelled on the date that Dr Perry ceased to be a director of the Company, being 12 December 2022 (United States) / 13 December 2022 (Australia), in accordance with the terms of the Options. Dr Perry continues to hold the Vested Options which have an expiry date of 28 December 2022 (United States) / 29 December 2022 (Australia).

⁺ See chapter 19 for defined terms.

Part 2 - Director's relevant interests in securities of which the director is not the registered holder

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Name of holder & nature of interest Note: Provide details of the circumstances giving rise to the relevant interest	Number & class of securities
N/A	N/A

Part 3 - Director's interests in contracts

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
No. and class of securities to which interest relates	N/A
merestrelates	

Appendix 3Z Page 2 11/3/2002

⁺ See chapter 19 for defined terms.